Secretin Enhanced MRCP for Evaluation of the Known or Suspected Intraductal Papillary Mucinous Neoplasms of the Pancreas

NCT00621556 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

2

Enrollment

OTHER

Sponsor class

Stopped Poor patient enrollment due to logistical issues

Conditions

Intraductal Papillary Mucinous Neoplasms

Interventions

DRUG: RG1068 (Synthetic Human Secretin)

Sponsor

Massachusetts General Hospital